REMEGEN

Grace Liu from Sino Biological discusses Antibody-Drug Conjugates (ADCs), a cancer therapy combining precision targeting with potent cytotoxic drugs. ADCs consist of a monoclonal antibody, cytotoxic payload, and linker, balancing efficacy and safety. Sino Biological offers comprehensive ADC development solutions, aiding in the complex process from discovery to clinical studies.

On Dec 12, 2024, RemeGen presented phase III study data of Disitamab Vedotin (DV) for HER2-positive advanced breast cancer with liver metastasis at the 47th SABCS. This is the first global prospective randomized phase III study on a HER2-targeting ADC showing significant efficacy.

DelveInsight's report on Urothelial Carcinoma Market (2020-2034) highlights market trends, epidemiology, and key companies/therapies. The market size was ~USD 900 million in 2023, expected to grow significantly. Key companies include Merck, Bristol Myers Squibb, and others. Therapies like KEYTRUDA and OPDIVO are prominent. The U.S. leads in market share and incident cases. Pipeline candidates and increased awareness drive market growth.

DelveInsight's report highlights a robust lupus nephritis pipeline with 30+ companies developing 35+ therapies, including key players like AstraZeneca and Novartis. Promising therapies like Anifrolumab and Ianalumab are in various clinical phases, with recent updates from companies like Adicet Bio and Kyverna Therapeutics. The report provides comprehensive insights into the pipeline, therapeutic assessments, and market dynamics.

The global antibody drug conjugate market is projected to grow from USD 7.72 billion to USD 23.3 billion by 2035, driven by advancements in antibody engineering and clinical trial successes. Over 280 ADCs are approved or in clinical studies, with 250+ in early development. Key segments include breast cancer, solid tumors, and HER-2 antigen. North America leads in market share, while Asia-Pacific shows higher growth potential.

The 'Lupus Nephritis - Pipeline Insight, 2024' report by ResearchAndMarkets.com provides a comprehensive overview of the current and future prospects of Lupus Nephritis treatments. It details the pipeline landscape, including disease overview, treatment guidelines, and assessments of emerging drugs like QLG1074, ADX-097, KYV-101, CABA-201, and NKX019. The report highlights ongoing R&D efforts, key collaborations, and trends in drug development, focusing on novel approaches to improve disease management. It also covers clinical trial stages, route of administration, and molecule types, identifying unmet needs and the impact of emerging therapies.

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report highlights 75+ companies developing 80+ therapies, including promising candidates like GA Depot, Remibrutinib, and IMU 838. Key events include Immunic's positive Phase 3 ENSURE trial interim analysis, Roche's FDA approval for Ocrevus injectable, and Sanofi's mixed results for tolebrutinib in Phase III trials. The report covers global pipeline stages, product types, molecule types, mechanisms of action, and routes of administration.

The article discusses the importance of enabling JavaScript for optimal app performance.

The ADC market, driven by technological advancements and personalized medicine, is expected to reach ~USD 26 billion by 2030 with a CAGR of ~14%. North America leads due to high cancer incidence and strong biopharmaceutical sector. Key players include F. Hoffmann-La Roche Ltd, DAIICHI SANKYO COMPANY, LIMITED, and Pfizer Inc. The market is dynamic, influenced by regulatory frameworks and innovation in linker technologies and payloads.

UCB and Biogen report positive Phase III PHOENYCS GO trial results for dapirolizumab pegol in moderate-to-severe SLE, with a second Phase 3 trial, PHOENYCS FLY, planned for 2024. The SLE market is expected to grow from USD 3.2 billion in 2023, driven by emerging therapies like Litifilimab, Ianalumab, and Cenerimod.